The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂

Pharmacology, Toxicology and Pharmaceutical Science

• Atorvastatin 71%
• 1 Alkyl 2 Acetylglycerophosphocholine Esterase 71%
• Statin (Protein) 57%
• Interleukin 6 42%
• Lipid 28%
• Fibrinogen 28%
• Monocyte Chemotactic Protein 1 28%
• Low Density Lipoprotein Cholesterol 28%
• Monotherapy 28%
• Atorvastatin Plus Ezetimibe 28%
• Biological Marker 14%
• Thrombosis 14%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 14%
• Ezetimibe 14%
• Pharmaceutical Therapy 14%

Biochemistry, Genetics and Molecular Biology

• Atorvastatin 100%
• Lipoprotein-Associated Phospholipase A2 71%
• Interleukin 6 42%
• Low-Density Lipoprotein 28%
• Cholesterol 28%
• Monocyte 28%
• Fibrinogen 28%
• Low Drug Dose 28%
• Protein 28%
• Lipid 28%
• Electric Potential 14%
• Reduction (Chemistry) 14%
• Pleiotropy 14%
• Lipoprotein Blood Level 14%